Considerations for pre-transfusion immunohaematology testing in patients receiving the anti-CD38 monoclonal antibody daratumumab for the treatment of multiple myeloma

This article summarises daratumumab’s effects on pre-transfusion immunohaematology testing and its impact on clinical practice and makes practical recommendations based on a consensus from medical and scientific transfusion experts and myeloma specialists on behalf of the Australian and New Zealand Society of Blood Transfusion and Myeloma Scientific Advisory Group to Myeloma Australia, respectively.

You can link to the article here, or download from our ANZSBT Position & Consensus Statements page.